BrainStorm Prepares to Share Q2 Financial Results and Updates
BrainStorm Set to Announce Financial Results and Corporate Update
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a prominent innovator in adult stem cell therapies for neurodegenerative diseases, is gearing up to share its second quarter financial results. This much-anticipated conference call is scheduled for 8:30 AM Eastern Time on an upcoming date. The call aims to offer vital updates and insights for current and potential shareholders.
Key Participants in the Upcoming Conference Call
The conference call will feature BrainStorm's President and Chief Executive Officer, Chaim Lebovits. Joining him will be the Chief Operating Officer, Hartoun Hartounian, Ph.D.; Chief Medical Officer, Bob Dagher, M.D.; and Interim Chief Financial Officer, Alla Patlis. This expert team will present a comprehensive overview of the financial developments and follow it with a Q&A session where attendees can ask their questions directly.
How to Participate in the Call and Submit Questions
Shareholders and interested parties can participate in the call by dialing the specified access numbers. The U.S. toll-free number is 877-545-0320, while international participants can join at 973-528-0002. When dialing in, use the participant access code 601260 to gain entry.
Participants are encouraged to submit their inquiries ahead of the call. Questions must be submitted by 10:00 AM Eastern Time, so everyone is invited to share their thoughts and receive insights during this interactive session.
Replay of the Conference Call
For those who cannot attend the live event, a replay will be available shortly after the call ends. Interested individuals can listen to the replay by calling the toll-free number at 877-481-4010 or the international number at 919-882-2331, using the replay passcode 52831. The opportunity to listen will extend until a future date.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. specializes in developing advanced autologous adult stem cell therapies to combat debilitating neurodegenerative diseases. Its flagship product, NurOwn, is derived from the company's proprietary platform utilizing autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells. This innovative approach aims to regulate neuroinflammation and enhance neuroprotection, providing hope to many patients and families.
The NurOwn therapy has shown promise in clinical applications, particularly for conditions such as amyotrophic lateral sclerosis (ALS). Now, a Phase 3 trial has recently been concluded, paving the way for further exploration and potential therapeutic solutions. Meanwhile, a second Phase 3b trial is underway under an agreement with regulatory authorities, demonstrating the company's commitment to advancing research and care options.
BrainStorm's research initiatives have provided valuable insights into ALS's biological mechanisms, which include pharmacogenomic responses and extensive biomarker data analytics. The company has received favorable attention from the scientific community, publishing findings in esteemed peer-reviewed journals.
In addition to its ALS research, BrainStorm has garnered attention for its work on multiple sclerosis and its exploration of a proprietary, allogeneic exosome-based platform for delivering therapeutic proteins and nucleic acids. The recent allowance of a foundational patent for its exosome technology reinforces BrainStorm's robust intellectual property portfolio and position in the regenerative medicine field. Let's learn more about their innovative approaches and contributions online.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to update shareholders on the second quarter financial results and provide insights from key company executives.
Who will be participating in the call?
Key participants include President Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis.
How can participants submit questions for the call?
Participants can submit their questions via email before 10:00 AM Eastern Time prior to the call.
Is there a replay available for the conference call?
Yes, a replay will be available through specified numbers after the call concludes, using a replay passcode.
What is BrainStorm’s main area of focus?
BrainStorm focuses on developing adult stem cell therapies for neurodegenerative diseases, with its leading product being NurOwn for ALS.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.